- Home
- CNSP vs VRAX Comparison
CNSP vs VRAX Comparison
Compare CNSP & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- VRAX
- Stock Information
- Founded
- CNSP 2017
- VRAX 2013
- Country
- CNSP United States
- VRAX United Kingdom
- Employees
- CNSP N/A
- VRAX N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNSP Health Care
- VRAX Health Care
- Exchange
- CNSP Nasdaq
- VRAX Nasdaq
- Market Cap
- CNSP 5.6M
- VRAX 5.9M
- IPO Year
- CNSP 2019
- VRAX 2022
- Fundamental
- Price
- CNSP $1.25
- VRAX $1.14
- Analyst Decision
- CNSP Hold
- VRAX Strong Buy
- Analyst Count
- CNSP 1
- VRAX 1
- Target Price
- CNSP N/A
- VRAX $3.00
- AVG Volume (30 Days)
- CNSP 332.7K
- VRAX 123.9K
- Earning Date
- CNSP 05-14-2025
- VRAX 02-05-2025
- Dividend Yield
- CNSP N/A
- VRAX N/A
- EPS Growth
- CNSP N/A
- VRAX N/A
- EPS
- CNSP N/A
- VRAX N/A
- Revenue
- CNSP N/A
- VRAX $84,872.00
- Revenue This Year
- CNSP N/A
- VRAX $5,169.18
- Revenue Next Year
- CNSP N/A
- VRAX $66.97
- P/E Ratio
- CNSP N/A
- VRAX N/A
- Revenue Growth
- CNSP N/A
- VRAX 7.03
- 52 Week Low
- CNSP $1.21
- VRAX $0.60
- 52 Week High
- CNSP $800.00
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- CNSP 30.28
- VRAX 34.78
- Support Level
- CNSP $1.28
- VRAX $1.10
- Resistance Level
- CNSP $1.46
- VRAX $1.35
- Average True Range (ATR)
- CNSP 0.38
- VRAX 0.09
- MACD
- CNSP -0.12
- VRAX 0.00
- Stochastic Oscillator
- CNSP 1.18
- VRAX 19.44
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.